Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Remune Virologic Response Data Is At Center Of Publication Dispute

  • News

Executive Summary

The dispute between a University of California at San Francisco researcher and Immune Response over publication of results from a Remune study focuses on the presentation of virologic response data.

You may also be interested in...



Conflict of Interest Policy Limits Industry Control Over Studies, Publication

Sponsors will have a limited time to review manuscripts before publication, a revised conflict of interest policy from the major medical journals states.

Conflict of Interest Policy Limits Industry Control Over Studies, Publication

Sponsors will have a limited time to review manuscripts before publication, a revised conflict of interest policy from the major medical journals states.

Immune Response Remune Trials To Continue After Agouron Drops Rights

Immune Response Corporation will continue clinical trials for the HIV therapy Remune (HIV-1 immunogen) following the decision by Pfizer subsidiary Agouron to drop its rights to develop and market the product, IRC said July 6.

Table

View full table

Tags:
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS036856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By